Evidence map›Paper›PMID 29108400›Full record

ArticleThe Korean journal of internal medicine2018

Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.

Osung Kwon, Jung-Min Ahn, Do-Yoon Kang, Se Hun Kang, Pil Hyung Lee, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Osung KwonDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jung-Min AhnDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Do-Yoon KangDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Se Hun KangDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Pil Hyung LeeDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Soo-Jin KangDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seung-Whan LeeDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Young-Hak KimDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cheol Whan LeeDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seong-Wook ParkDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Duk-Woo ParkDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seung-Jung ParkDepartment of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ulsan College · KRUniversity of Ulsan · KRAsan Medical Center · KR

Funding

Cardio Vascular Research Foundation
6 · The paper itself

Abstract

BACKGROUND/

aimsCompared with metallic drug-eluting stents (DES), bioresorbable vascular scaffolds (BVS) may further improve long-term outcomes of percutaneous coronary intervention (PCI) in patients with coronary artery disease. We report our early experience with BVS in Korea.

methodsWe evaluated 105 consecutive patients with BVS implanted at Asan Medical Center, Korea between October 21, 2015 and June 3, 2016. Angiographic results, and in-hospital and 6-month clinical outcomes were assessed.

resultsA total of 134 BVS were implanted to treat 115 lesions. The mean age was 62 ± 10.5 years; 85 patients (81%) were males, 26 patients (25%) were presented with acute coronary syndrome. Among 115 lesions treated with BVS, 76 (66.1%) were B2/C type, 27 (23.5%) were bifurcation lesions, and four (3.5%) were chronic total occlusion. Pre-dilation and post-dilation using high-pressure non-compliant balloon was performed in 104 lesions (90.4%) and 113 lesions (98.2%), respectively. During the procedure, intravascular imaging was used for all patients (100%; intravascular ultrasound 89 and optical coherence tomography 40 patients). Device success rate was 100%. In-segment and in-scaffold acute again were 1.1 ± 0.6 and 1.3 ± 0.5 mm, respectively. Periprocedural myocardial infraction occurred in four patients (3.8%). No deaths, stent thrombosis, or urgent revascularizations occurred either during hospitalization or the follow-up period.

conclusionIn this single-center experience, implantation of BVS with intravascular imaging support was feasible and early clinical outcomes were excellent. Evaluation of long-term efficacy and safety of BVS and its feasibility in clinical use for a broader range of lesions is warranted.

Indexed as

Coronary Artery DiseaseDrug-Eluting StentsEverolimusImmunosuppressive AgentsAbsorbable ImplantsAgedCoronary AngiographyFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionProsthesis DesignRepublic of KoreaTreatment OutcomeEverolimusImmunosuppressive AgentsAbsorbable implantsBioresorbable vascular scaffoldsPercutaneous coronary intervention

Identifiers

PMID29108400
PMCPMC6129626
OpenAlexW2767491966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.